TABLE 4.
Therapy efficacy and safety results.
| API (N = 50) | RIV (N = 110) | DAB (N = 21) | LMWH/VKA (N = 50) | |
|---|---|---|---|---|
| Efficacy (%) | ||||
| Cure | 22.0 | 2.7 | 4.8 | 6.0 |
| Improvement | 72.0 | 92.8 | 90.4 | 76.0 |
| Therapy favorable | 94.0 | 95.5 | 95.2 | 82.0 |
| safety (%) | ||||
| Mortality | 2.0 | 1.8 | 0.0 | 0.0 |
| MB | 0.0 | 0.0 | 0.0 | 0.0 |
| CRNMB | 2.0 | 2.7 | 4.8 | 10.0 |
| VTE off-treatment | 2.0 | 2.7 | 0.0 | 8.0 |
| Therapy unfavorable | 6.0 | 4.5 | 4.8 | 18.0 |
MB, major bleeding; CRNMB, clinically relevant non-major bleeding; VTE, venous thromboembolism. API, apixaban; RIV, rivaroxaban; DAB, dabigatran; LMWH/VKA, low molecular weight heparin followed by vitamin K antagonist.